Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HengLi (Botulinum Toxin Type A) in Trigeminal Neuralgia
NCT06410859Phase 2Enrolling by invitation
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lanbotulinumtoxin-A in trigeminal neuralgia (TN) (3 arms). Primary endpoint: Efficacy of different dosing regimens based on VAS score, DSIS score, daily pain duration, and number of daily pain episodes at 12 weeks. Started Apr 2024; status: enrolling by invitation.
02
Drugs
lanbotulinumtoxin-A
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT06410859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06410859.